Top 6 Companies in the Human Papillomavirus (HPV) Vaccine Market

The human papillomavirus (HPV) vaccine market was valued at USD 5.22 billion in 2023. It is expected to grow at a CAGR of 11.60% during the forecast period of 2024-2032, with the value likely to reach USD 13.96 billion by 2032. The market is driven by the rising incidence of human papillomavirus-related disease and technological advancements in vaccine technology across the 8 major markets.

The human papillomavirus vaccine helps prevent human papillomavirus, a prevalent sexually transmitted infection that leads to genital warts and certain types of cancer. Human papillomavirus is transmitted through sexual contact and is classified into high-risk strains associated with cancer. Even though most infections clear up without treatment, persistent infections may result in cancer. Regular screening and vaccination are crucial in handling health risks associated with human papillomavirus, supported by organizations such as the World Health Organization (WHO). Human papillomavirus can be spread through direct contact with skin during sexual activity, impacting genital, oral, and throat regions. Several carriers can spread the virus without exhibiting any symptoms. Vaccination decreases the likelihood of human papillomavirus-related cancers, safeguarding individuals of both sexes.

The market is influenced by an increase in the burden of human papillomavirus-related illnesses, with around 47,984 new cases of human papillomavirus-related cancer reported in the United States each year. Advancements in human papillomavirus vaccinations, like Gardasil 9, have enhanced their efficacy in preventing various cancers. Ongoing research aims to create single-dose and combination vaccines to streamline immunization procedures, particularly in resource-limited areas. Healthcare providers and governments are using more of these modern vaccines to combat the global impact of human papillomavirus-related illnesses, resulting in a positive forecast for market growth.

In October 2024, the World Health Organization confirmed the use of Cecolin®, a one-shot human papillomavirus vaccine developed by Xiamen Innovax Biotech Co., Ltd. The vaccine focuses on human papillomavirus strains 16 and 18. This authorization improves the global availability of human papillomavirus vaccines, particularly in nations encountering cost or availability difficulties. Such advancement and acceptance of the human papillomavirus vaccine is likely to elevate the market value significantly in the coming years.

Let’s explore the profile of top companies leading the human papillomavirus (HPV) vaccine market in 2024.

1.    Merck & Co., Inc.

Merck & Co., Inc., a pharmaceutical company headquartered in New Jersey, specializes in prescription drugs, biologic treatments, and vaccinations. In September 2024, they announced successful Phase 3 trial outcomes for GARDASIL®9 in Japanese men between the ages of 16 and 26. The vaccine is administered to females between the ages of 9 and 45 to prevent different cancers and lesions caused by certain strains of human papillomavirus (HPV).

2.    GlaxoSmithKline plc.

GSK plc, a UK-based pharmaceutical company established in 2000, specializes in developing, producing, and selling drugs and vaccines. In May 2022, China’s National Medical Products Administration (NMPA) authorized the two-dose schedule of GSK's Cervarix vaccine for human papillomavirus types 16 and 18 in girls aged 9 to 14, intending to prevent cervical cancer and human papillomavirus-related illnesses. This approval increases the availability of vaccinations and can aid in lowering the incidence of cervical cancer in China, where prevalence is elevated.

3.    Johnson & Johnson Services, Inc.

Johnson & Johnson (J&J) is a top pharmaceutical and medical device company. The company’s subsidiaries offer medications for different illnesses and medical equipment for heart, bone, and brain treatment. Janssen Pharmaceuticals, a branch of Johnson & Johnson, partnered with Bavarian Nordic to create vaccines for human papillomavirus and hepatitis B using Bavarian Nordic's MVA-BN® technology.

4.    Serum Institute of India Pvt. Ltd.

The Serum Institute of India located in Pune is a leading biotechnology firm and the largest vaccine manufacturer globally. They have collaborated with the Indian government to develop Cervavac, the first human papillomavirus vaccine in India. The Institute's goal is to expand the availability of their human papillomavirus vaccine at discounted prices for a government immunization drive to reduce the annual number of 70,000 women's deaths from cervical cancer in India.

5.    Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals, Inc. is a US-based biotechnology company that focuses on developing synthetic DNA products for treating cancer and infectious diseases. The company’s FDA breakthrough therapy designation for INO -3107 in September 2023 marks its debut in the human papillomavirus vaccine market, focusing on ailments such as recurrent respiratory papillomatosis related to human papillomavirus types 6 and 11. This DNA medicine aims to improve existing treatments and highlights INOVIO's commitment to addressing human papillomavirus-associated health issues through therapeutic interventions.

6.    Walvax Biotechnology Co., Ltd.

Walvax Biotechnology Co., Ltd. develops vaccines and blood products, including the Haemophilus influenza vaccine for meningitis. The company also offers medications for pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. In August 2024, Zerun Bio's new human papillomavirus vaccine, Walrinvax™, reached a significant milestone by obtaining WHO prequalification. This dual-purpose vaccine focuses on human papillomavirus 16 and 18 strains, which cause 70% of cervical cancer cases, providing a cost-effective vaccination solution for countries dealing with supply issues.